CLARITY-Gastric 01 at ESMO 2026: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer
CLARITY-Gastric 01 at ESMO 2026: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer Oncodaily
Онкология
🎗️Лента новостей
Онкология
Новые биомаркеры открывают больше возможностей для ранней диагностики рака печени.
Новые биомаркеры открывают больше возможностей для ранней диагностики рака печени. Vietnam.vn
Онкология
В РКФ назвали симптомы, которые могут указывать на рак у собаки
В РКФ назвали симптомы, которые могут указывать на рак у собаки The World Inform
Онкология
At ESMO, AstraZeneca’s cancer pursuits get a showcase
At ESMO, AstraZeneca’s cancer pursuits get a showcase STAT
Онкология
Obituary: As She Faced Cancer Herself, Dr. Rachna Shroff Worked to Transform Treatment for Others
Obituary: As She Faced Cancer Herself, Dr. Rachna Shroff Worked to Transform Treatment for Others INDIA New England News
Онкология
AstraZeneca stomach cancer drug doubles survival in late-stage trial (AZN:NYSE)
AstraZeneca stomach cancer drug doubles survival in late-stage trial (AZN:NYSE) Seeking Alpha
🎗️
Онкология
Experts at ESMO Unsure if ctDNA Should Alter Intensification Strategy With NSCLC Targeted Therapy
Experts at ESMO Unsure if ctDNA Should Alter Intensification Strategy With NSCLC Targeted Therapy GenomeWeb
Онкология
Can a supplement help with brain fog after breast cancer treatment?
Can a supplement help with brain fog after breast cancer treatment? Medical News Today
Онкология
FDA Approves Jemperli for Certain Patients With Locally Advanced Rectal Cancer
FDA Approves Jemperli for Certain Patients With Locally Advanced Rectal Cancer news.cancerconnect.com
Онкология
Dégi László Csaba: Journal of Breakthroughs in Immuno-Oncology Launches With New Editorial Board
Dégi László Csaba: Journal of Breakthroughs in Immuno-Oncology Launches With New Editorial Board Oncodaily
🎗️
Онкология
Astra’s Experimental Stomach Cancer Drug Doubled Survival Time
Astra’s Experimental Stomach Cancer Drug Doubled Survival Time Bloomberg.com
Онкология
ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer | Newswise
ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer | Newswise Newswise
🎗️
Онкология
TOP-1 Study Reports 14.8% Five-Year Local Recurrence After Radiotherapy Omission in Older Women With Breast Cancer
TOP-1 Study Reports 14.8% Five-Year Local Recurrence After Radiotherapy Omission in Older Women With Breast Cancer Oncodaily